Navigation Links
Nile Therapeutics, Inc. to Present at Upcoming BIO CEO & Investor Conference
Date:2/5/2008

BERKELEY, Calif., Feb. 5 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (OTC Bulletin Board: NILT), announced today that Peter M. Strumph, Chief Executive Officer, will present at the BIO CEO & Investor Conference at the Waldorf-Astoria Hotel in New York City on Tuesday, February 12, 2008 at 11:00 a.m. EST. Mr. Strumph will provide an overview of Nile and an update on its clinical development programs.

The presentation will be webcast live and can be accessed by visiting the Investor Relations section at http://www.nilethera.com. The webcast will be archived for ninety days. Additional information regarding the BIO Investor Forum can be accessed at http://ceo.bio.org.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical need. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel chimeric peptide in Phase I studies for the treatment of acute decompensated heart failure, and 2NTX-99, a small molecule, pre-clinical, anti-atherothrombotic agent with nitric oxide donating properties. A key component of the Company's strategy is to acquire the global rights to additional compounds to expand its portfolio. More information on Nile can be found at http://www.nilethera.com.

Contact:

Daron Evans

Chief Financial Officer

Nile Therapeutics, Inc.

510-281-7700

info@nilethera.com

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of histor
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Velcura Therapeutics, Inc. Teams with International Discovery Sourcing Consultants to Develop New Therapeutic Molecules for Cancer and Bone Disease
2. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
3. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
4. Cell Therapeutics, Inc. (CTI) Shareholders Authorize Share Increase at Special Meeting of Shareholders
5. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
6. Cell Therapeutics, Inc. (CTI) Prices $1.27 million (euros 856.000) Offering of Common Stock through Societe Generale
7. Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus
8. Cell Therapeutics, Inc. (CTI) Hosts Conference Call to Discuss Update on Zevalin(R) Acquisition, CMS Reimbursement, and PIX301 Timeline
9. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
10. Cell Therapeutics, Inc. (CTI) to Submit Marketing Authorization Application for XYOTAX(TM) for First-line Non-small Cell Lung Cancer Ahead of Schedule
11. Cell Therapeutics, Inc. Announces Issuance of $23.25 Million in New Convertible Senior Notes in Exchange for $36.08 Million of Existing Convertible Senior Subordinated and Subordinated Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 Research and Markets  has ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... http://photos.prnewswire.com/prnh/20130307/600769 ... (either DNA or RNA) into cells. This technology helps ... cells and protein metabolism by affecting the nuclear genes. ...
(Date:7/11/2014)... MISSISSAUGA, ON , July 11, 2014 /CNW/ - ... Canada approved APTIOM TM (eslicarbazepine acetate) for use ... partial-onset seizures in patients with epilepsy who are not ... not indicated for use in patients under 18 years ... the most common neurological disorders and according to Epilepsy ...
(Date:7/10/2014)... Women in the West African ... additional family planning option. Sayana® Press has the ... levels of the health system and in communities ... used contraceptive—Pfizer’s Depo-Provera® (depot medroxyprogesterone acetate)—with the BD ... first of four African countries expected to begin ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Understanding the ... channel-expressing cell lines, and the gap that currently exists ... that expand its industry-leading portfolio of validated ion channel ... ion channel-expressing cell lines, as ion channels control many ... control this activity creates the potential to treat a ...
Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3
... ever admit to buying technology for technologys sake. And yet ... and deploy technology could be forgiven for believing thats what ... energy into specifying, acquiring and implementing the technology and almost ... that it is supposed to serve. From the way we ...
... giving birth to a new product, behave just like ... typical hysterical hoopla of the incubation wing is often ... becomes a subdued Dilbertish style revolution. Objects do fly, ... harmless, foamy projectiles. Everyone shares the excitement and all ...
... Financial Institutions MADISON, Wis. The Wisconsin ... low profile, although its actions have a significant ... department is going through a renaissance and increasing ... of Secretary Lorrie Keating Heinemann. , ,The DFI ...
Cached Biology Technology:Why are you buying technology? 2Why are you buying technology? 3Naming that thing... again? 2Naming that thing... again? 3Naming that thing... again? 4Wisconsin seeks to develop $10 million angel investment fund 2Wisconsin seeks to develop $10 million angel investment fund 3Wisconsin seeks to develop $10 million angel investment fund 4Wisconsin seeks to develop $10 million angel investment fund 5
(Date:7/11/2014)... Stem Cell scientists have set a "mouse TRAP" to ... by a recent study published in the Journal ... uses a technique called TRAP to extract cellular and ... Invented by scientists at the Rockefeller Institute for Medical ... to the protein-making machinery, or ribosomes, of the cell ...
(Date:7/11/2014)... of researchers, including scientists from the Max Planck Institute ... a major step in understanding photosynthesis, the process by ... oxygen in its atmosphere and which is therefore crucial ... , The researchers report the first direct visualization of ... step in which a specific protein complex, photosystem II, ...
(Date:7/11/2014)... division of the striatum is also involved in ... of substance P in the striatal marginal division ... his team, College of Biophotonics, South China Normal ... P receptor, neurokinin 1 was highly expressed in ... rats. Unilateral or bilateral injection of an antisense ...
Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2
... scientists at the American Museum of Natural History suggests that ... food sources. As Arctic sea ice melts earlier and freezes ... time to hunt their historically preferred preyringed seal pupsand must ... at least some polar bears in the western Hudson Bay ...
... children exposed to high levels of air pollutants were nearly ... children and lower levels of pollution exposure, report researchers at ... obesity and asthma have both increased dramatically in the past ... has increased from 7% in 1980 to 20% in 2008. ...
... with unique strands of DNA like barcodes ... a billion prototype drug molecules for anti-cancer activity, ... Institute of Cancer Research, London, Cancer Research Technology ... Researchers will use Nuevolution,s novel screening technology, ...
Cached Biology News:Polar bear diet changes as sea ice melts 2Obese children more susceptible to asthma from air pollution 2International deal to screen potential cancer drugs using DNA 'barcodes' 2International deal to screen potential cancer drugs using DNA 'barcodes' 3
ssDNA from PCR DNA in less than 1 hour. No gels, columns, or slurries. Sequence from high quality ssDNA: clearer reads, longer runs....
Applications: Immunohistochemistry, ISH, FISH, CISH....
... fit into the Universal Test ... to greatly increase your microplate ... plates at an angle, and ... shaker at once for quick ...
Mixing speed from 750-3200RPM, small vortexing orbit of1.0mm...
Biology Products: